Avadel Pharmaceuticals plc (NASDAQ: AVDL) kicked off on Tuesday, up 2.63% from the previous trading day, before settling in for the closing price of $7.97. Over the past 52 weeks, AVDL has traded in a range of $7.39-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -40.57% over the past five years. While this was happening, its average annual earnings per share was recorded 75.00%. With a float of $88.11 million, this company’s outstanding shares have now reached $96.34 million.
Let’s look at the performance matrix of the company that is accounted for 154 employees. In terms of profitability, gross margin is 91.92%, operating margin of -46.33%, and the pretax margin is -52.84%.
Avadel Pharmaceuticals plc (AVDL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Avadel Pharmaceuticals plc is 8.57%, while institutional ownership is 74.73%. The most recent insider transaction that took place on Jan 21 ’25, was worth 39,640. In this transaction Director of this company bought 5,000 shares at a rate of $7.93, taking the stock ownership to the 67,900 shares. Before that another transaction happened on Jan 13 ’25, when Company’s Director bought 10,000 for $8.04, making the entire transaction worth $80,450. This insider now owns 104,055 shares in total.
Avadel Pharmaceuticals plc (AVDL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.00% per share during the next fiscal year.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Take a look at Avadel Pharmaceuticals plc’s (AVDL) current performance indicators. Last quarter, stock had a quick ratio of 2.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
Avadel Pharmaceuticals plc (NASDAQ: AVDL) saw its 5-day average volume 1.21 million, a negative change from its year-to-date volume of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 86.15%. Additionally, its Average True Range was 0.49.
During the past 100 days, Avadel Pharmaceuticals plc’s (AVDL) raw stochastic average was set at 8.52%, which indicates a significant decrease from 58.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.87% in the past 14 days, which was lower than the 80.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.69, while its 200-day Moving Average is $13.75. Nevertheless, the first resistance level for the watch stands at $8.32 in the near term. At $8.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.72. If the price goes on to break the first support level at $7.92, it is likely to go to the next support level at $7.65. Assuming the price breaks the second support level, the third support level stands at $7.52.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Key Stats
The company with the Market Capitalisation of 788.22 million has total of 96,362K Shares Outstanding. Its annual sales at the moment are 27,960 K in contrast with the sum of -160,280 K annual income. Company’s last quarter sales were recorded 50,030 K and last quarter income was -2,630 K.
